1 Week Diet

Check our Recent Posts

 Total no of Ideas: 11176 
February 14, 2019

Empagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Empagliflozin(EMBA) (Brand name: Jardiance), a drug used in the treatment of TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 14/February/2018, 10.54 pm

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]
February 14, 2019

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA DANCR  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and aging, via down-regulation of its target gene, 14/February/2019, 6.48 am

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]
February 14, 2019

Immune enhancement therapy: Ezetimibe, a drug used in the treatment of dyslipidemia, increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 14/February/2019, 6.41 am

Introduction: What they say:   A recent study from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China shows that “Sox2 functions as a sequence-specific DNA sensor in […]
February 14, 2019

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 14/February/2019, 6.29 am

Introduction: What they say:  A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on […]
February 14, 2019

Molecular therapy for Malaria: Probucol, a drug used in the treatment of dyslipidemia, increases Ferroportin expression, decreases intracellular iron accumulation, inhibits cellular damage, prevents hemolysis, and inhibits malaria infection, via upregulation of its target gene, 14/February/2019, 6.21 am

Introduction: What they say: A study from the Section on Human Iron Metabolism, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes […]
February 12, 2019

Ribonucleic acid-based therapy for aging-associated diseases and Lifespan extension: LncRNA PCGEM1 (Prostate-specific transcript 1)  inhibits the interaction of DBC1 with PARP1, increases the PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer, and ageing, via down-regulation of its target gene, 12/February/2019, 11.14 pm

Introduction: What they say A study from Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA; and […]
February 12, 2019

Combinatorial therapy for cancer: A therapeutic mix encompassing Metformin and Navitoclax/ABT-263 (MAN) increases the expression of mitochondrial protein LACTB, decreases levels of mitochondrial phosphatidylserine decarboxylase, alters mitochondrial lipid metabolism, and promotes differentiation of breast cancer cells via up-regulation of its target gene, 12/February/2018, 10.31 pm

Introduction: What they say: A study from the Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts, USA, Department of Biology, Massachusetts Institute of Technology, […]
February 12, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA HEIH  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 10.21 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
February 12, 2019

Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing  a therapeutic mix encompassing Metformin and Navitoclax/ABT-263   inhibits BMI1 and AP-1 expression, overcomes chemotherapeutic resistance, promotes chemosensitivity, suppresses cancer stem cells in HNSCC, and inhibits lymph node metastasis, via down-regulation of its target genes, 12/February/2017, 10.13 pm

Introduction: What they say: A study from the Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, Jonsson Comprehensive Cancer Center and Broad Stem Cell Research […]
February 12, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA  ILF3-AS1  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/Februay/2019, 9.56 pm

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]
February 10, 2019

Combinatorial therapy for Metastatic human tumors:  A pharmaceutical mixture encompassing metformin and Navitoclax/ABT-263 (MAN)  decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via upregulation of its target gene, 11/February/2017, 12.34 am

Introduction: What they say: A study from the State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, School of Life Sciences, Xiamen […]
February 10, 2019

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA ATB increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 11/Februay/2019, 12.19 am

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center […]

Who we are and what we do

Dr Boominathan’s quote on Science

Science is not about how to follow the conventions, but about how not to follow the conventions